Infectious Disease Research Institute

Access To Advanced Health Institute

University of Virginia Patent Foundation

Immune Design Corp.

Hawaii Biotech, Inc.

Neal Van Hoeven

Christopher B Fox

Amit Praful Khandhar

Susan S Lin

Darrick Carter

William A Petri

Mayuresh M Abhyankar

Mark T Orr

Anwar Ahniyaz

James Maurice Allen

Thomas W Dubensky, Jr

Jesse Erasmus

David Edward Clements

Jesse H Erasmus

Traci Mikasa

Jin Zhong Li

Derek D Sloan

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

Nanoalum particles containing a pegylated lipid sizing agent

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

Pegylated liposomes and methods of use

Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

Nanostructured lipid carriers and stable emulsions and uses thereof

PEGylated liposomes and methods of use

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

Nanoalum particles comprising a PAA sizing agent

A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.

West nile virus vaccine and method of use thereof

Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).

Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Growing community of inventors

Seattle, WA, United States of America

Neal Van Hoeven